CMCarmine Musto

Carmine Musto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmine Musto has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sex Specificities of Patients Undergoing Coronary Procedures and Experiencing Transradial Approach Failures

    by Carmine Musto, Luca Paolucci, Giulia Nardi, Enrico Romagnoli, Flavia Belloni, Giovanni Farraiuoli, Giuseppe Talanas, Attilio Placanica, Massimo Mancone, Enrico Occhiuzzi, et al.

    The authors compared the outcomes of males and females experiencing crossover following a failed transradial approach. Original Contribution from Journal of Invasive Cardiology. Bleeding Coronary Angiography percutaneous coronary intervention Transradial access

  • Open Access

    Impact of balloon post‐dilation on valve durability and long‐term clinical outcomes after self‐expanding transcatheter aortic valve implantation

    by Jorge Sanz Sánchez, Damiano Regazzoli, Marco Barbanti, Claudia Fiorina, Marianna Adamo, Marco Angelillis, Marco De Carlo, Barbara Bellini, Matteo Montorfano, Antonio Mangieri, et al.

    Background: Balloon post‐dilation (BPD) is a widely adopted strategy to optimize acute results of TAVI, with a positive impact on both paravalvular leak and mean gradients. On the other hand, the inflation of the balloon inside prosthetic leaflets may damage them increasing the risk of structural valve deterioration (SVD). Furthermore, the impact of BPD on long‐term clinical outcomes and valve hemodynamics is yet unknown.Aims: To evaluate the impact of BPD on valve durability and long‐term clinical outcomes in patients undergoing self‐expanding transcatheter valve implantation (TAVI).Methods: Echocardiographic and clinical data from the ClinicalService (a nation‐based data repository and medical care project) were analyzed. Patients were divided into two groups, those who underwent BPD after TAVI and those who did not. Coprimary endpoints were all‐cause death and SVD. Cumulative incidence functions for SVD were estimated.Results: Among 1835 patients included in the study, 417 (22.7%) underwent BPD and 1418 (77.3%) did not undergo BPD. No statistically significant differences at 6‐year follow‐up were found between groups in terms of all‐cause mortality (HR: 1.05, 95% CI: 0.9–1.22; p = 0.557) and SVD (2.1% vs. 1.4%, p = 0.381). In addition, BPD did not predispose to higher risk of cardiovascular death, myocardial infarction, valve thrombosis, and endocarditis at 6‐year follow‐up.Conclusions: BPD following TAVI with a self‐expanding prosthesis does not seem to be associated with an increased risk of adverse clinical outcomes or SVD at 6‐year follow‐up.


  • Postprocedural trans‐mitral gradient in patients with degenerative mitral regurgitation undergoing mitral valve transcatheter edge‐to‐edge repair

    by Francesco De Felice, Luca Paolucci, Carmine Musto, Alberta Cifarelli, Silvio Coletta, Mauro Pennacchi, Rocco Stio, Domenico Gabrielli, Carmelo Grasso, Corrado Tamburino, et al.

    Background: The relationship between high postprocedural mean gradient (ppMG) and clinical events following mitral valve transcatheter edge‐to‐edge repair (MV‐TEER) in patients with degenerative mitral regurgitation (DMR) is still debated.Aim: The purpose of this study was to evaluate the effect of elevated ppMG after MV‐TEER on clinical events in patients with DMR at 1‐year follow‐up.Methods: The study included 371 patients with DMR treated with MV‐TEER enrolled in the “Multi‐center Italian Society of Interventional Cardiology (GISE) registry of trans‐catheter treatment of mitral valve regurgitation” (GIOTTO) registry. Patients were stratified in tertiles according to ppMG. Primary endpoint was a composite of all‐cause death and hospitalization due to heart failure at 1‐year follow‐up.Results: Patients were stratified as follows: 187 with a ppMG ≤ 3 mmHg, 77 with a ppMG > 3/=4 mmHg, and 107 with a ppMG > 4 mmHg. Clinical follow‐up was available in all subjects. At multivariate analysis, neither a ppMG > 4 mmHg nor a ppMG ≥ 5 mmHg were independently associated with the outcome. Notably, the risk of elevated residual MR (rMR > 2+) was significantly higher in patients belonging to the highest tertile of ppMG (p = 0.009). The association of ppMG > 4 mmHg and rMR ≥ 2+ was strongly and independently associated with adverse events (hazard ratio: 1.98; 95% confidence interval: [1.10–3.58]).Conclusions: In a real‐world cohort of patients suffering DMR and treated with MV‐TEER, isolated ppMG was not associated with the outcome at 1‐year follow‐up. A high proportion of patients showed both elevated ppMG and rMR and their combination appeared to be a strong predictor of adverse events.


  • Instantaneous wave‐free ratio‐guided revascularization of nonculprit lesions in STEMI patients with multivessel coronary disease: The WAVE registry

    by Carmine Musto, Massimiliano Scappaticci, Giuseppe Biondi‐Zoccai, Francesco De Felice, Domenico D'AMario, Marco S. Nazzaro, Rocco E. Stio, Armando Del Prete, Diana Chin, Mauro Pennacchi, et al.

    Background: Complete revascularization (CR) of nonculprit lesions (NCL) is strongly recommended in patients with ST‐elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), but no definitive evidence is available regarding which diagnostic strategy should be preferred. Instantaneous wave‐free ratio (iFR) has never been investigated in this setting. We aimed to describe clinical outcomes of a cohort of patients undergoing iFR‐guided CR.Methods: Following primary percutaneous coronary intervention (PCI), consecutive patients with STEMI and intermediate NCL were enrolled and destinated to an iFR‐guided CR. NCL with iFR ≤ 0.89 underwent PCI while NCL with iFR > 0.89 were deferred. The primary endpoint was NC target lesion failure (NC‐TLF) and the secondary endpoint was major adverse cardiovascular events (MACE), at 1‐year follow‐up.Results: Overall, 209 patients were enrolled (ischemic iFR = 83; nonischemic iFR = 126). Patients with ischemic iFR showed a higher prevalence of traditional cardiovascular risk factors and angiographically determined three‐vessel disease. In the entire cohort, NC‐TLF and MACE occurred in 6.7% and 10.5% of patients, respectively. Compared to the deferred group, patients with ischemic iFR experienced significantly higher rates of both NC‐TLF (3.2% vs. 12.1%; p = 0.021) and MACE (7.1% vs. 16.9%; p = 0.041). These results were mostly driven by increased rates of NC‐TLF PCI and further revascularizations in this latter group, while no differences were evident in terms of nonfatal myocardial infarction or death. At multivariable analysis, the strongest predictor of MACE was symptom onset to balloon time (HR = 1.17 [95% CI: 1.04–1.31], p = 0.008).Conclusions: In our study enrolling STEMI patients with MVD, iFR assessment was feasible and safe. PCI‐deferring according to iFR evaluation of NCL was associated with low rates of adverse events. Further randomized studies are needed to investigate the effectiveness of iFR‐guided revascularization compared to current practice in this setting.


  • Clinical outcomes and predictors in patients with previous cardiac surgery undergoing mitral valve transcatheter edge‐to‐edge repair

    by Francesco De Felice, Luca Paolucci, Carmine Musto, Alberta Cifarelli, Carmelo Grasso, Corrado Tamburino, Marianna Adamo, Paolo Denti, Arturo Giordano, Antonio L. Bartorelli, et al.

    Background: Mitral‐valve transcatheter edge‐to‐edge repair (MV‐TEER) is recommended in patients with severe functional mitral regurgitation (FMR) and in those with degenerative mitral regurgitation (DMR) not eligible to traditional surgery. Patients with a history of previous cardiac surgery are considered at high risk for surgical reintervention, but data are lacking regarding procedural and clinical outcomes.Objective: aim of this study was to assess the efficacy and clinical results of MV‐TEER in patients with previous cardiac surgery enrolled in the “multicentre Italian Society of Interventional Cardiology registry of transcatheter treatment of mitral valve regurgitation” (GIOTTO).Methods: Patients with previous coronary artery bypass grafting (CABG), surgical aortic valve replacement (AVR), or mitral valve repair (MVR) were included. Those with multiple or combined previous cardiac surgeries were excluded. Clinical follow‐up was performed at 30 days, 1 year, and 2 years. The primary endpoint was a composite of death or rehospitalization at 1‐ and 2‐year follow‐ups.Results: A total of 330 patients enrolled in the GIOTTO registry were considered (CABG 77.9%, AVR 14.2%, and MVR 7.9%). Most patients showed FMR (66.9%), moderate reduction of left ventricular (LV) ejection fraction, and signs of LV dilation. Procedural and device successes were 94.8% and 97%. At 1 and 2 years, the composite endpoint occurred are 29.1% and 52.4%, respectively. The composite outcome rates were similar across the three subgroups of previous cardiac surgery (p = 0.928) and between the FMR and DMR subgroups (p = 0.850) at 2 years. In a multivariate analysis, residual mitral regurgitation (rMR) ≥2+ was the main predictor of adverse events at 1 year (hazard ratio: 1.54 [95% confidence interval, CI: 1.00–2.38]; p = 0.050). This association was confirmed at 2 years of Kaplan–Meier analysis (p = 0.001).Conclusions: MV‐TEER is effective in these patients, regardless of the subtype of previous cardiac surgery and the MR etiology. An rMR ≥2+ is independently associated with adverse outcomes at 1‐year follow‐up.


  • Open Access

    A Case of Successful Use of the “Anchoring Technique” for Percutaneous Treatment of Left Ventricular Assist Device Graft Occlusion

    by Rocco Edoardo Stio, Andrea Montalto, Alfredo Intorcia, Vincenzo Polizzi, Mariano Feccia, Carmine Musto, Mauro Pennacchi, Luca Paolucci, Regina Stumpo, Emilio D’avino, et al.

    Left ventricular assist device (LVAD) obstruction can be a dramatic and life-threatening complication in patients with advanced heart failure (HF). Despite surgical redo is often required in these patients, it is associated with a high risk of periprocedural negative outcome. We report the case of a 68-year-old male with a thrombotic stenosis of the LVAD proximal outflow-graft. Following Heart Team debate, a percutaneous intervention was planned during veno-arterial Extra Corporeal Membrane Oxygenation (ECMO) assistance. To achieve the needed catheter support, we used the “distal balloon anchoring technique” through the outflow-graft and managed to implant a covered stent, rapidly restoring the flow through the LVAD. The patient was discharged without further complications. Our case shows that, in selected cases, percutaneous treatment of LVAD obstructions can be feasible, especially using advanced techniques derived from the experiences in coronary interventions and under ECMO assistance. More cases and prospective studies are mostly needed to explore long-term patency of the LVADs and clinical outcomes in these high-risk patients.


  • A Comparison Between Gore Cardioform and Amplatzer Septal Occluder for Percutaneous Closure of Patent Foramen Ovale Associated With Atrial Septal Aneurysm: Clinical and Echocardiographic Outcomes

    by Carmine Musto, Alberta Cifarelli, Francesco Dipasquale, Diana Chin, Marco Stefano Nazzaro, Rocco Edoardo Stio, Mauro Pennacchi, Francesco De Felice

    Dr. Musto and colleagues valuate the short- and long-term clinical and echocardiographic outcomes of the percutaneous closure of the patent foramen ovale (PFO) with an atrial septal aneurysm (ASA) using 2 different devices.


  • Open Access

    Gender Differences after Transcatheter Aortic Valve Replacement (TAVR): Insights from the Italian Clinical Service Project

    by Andrea Denegri, Michele Romano, Anna Sonia Petronio, Marco Angelillis, Cristina Giannini, Claudia Fiorina, Luca Branca, Marco Barbanti, Giuliano Costa, Nedy Brambilla, et al.

    Background: TAVR is a safe alternative to surgical aortic valve replacement (SAVR); however, sex-related differences are still debated. This research aimed to examine gender differences in a real-world transcatheter aortic valve replacement (TAVR) cohort. Methods: All-comer aortic stenosis (AS) patients undergoing TAVR with a Medtronic valve across 19 Italian sites were prospectively included in the Italian Clinical Service Project (NCT01007474) between 2007 and 2019. The primary endpoint was 1-year mortality. We also investigated 3-year mortality, and ischemic and hemorrhagic endpoints, and we performed a propensity score matching to assemble patients with similar baseline characteristics. Results: Out of 3821 patients, 2149 (56.2%) women were enrolled. Compared with men, women were older (83 ± 6 vs. 81 ± 6 years, p < 0.001), more likely to present severe renal impairment (GFR ≤ 30 mL/min, 26.3% vs. 16.3%, p < 0.001) but had less previous cardiovascular events (all p < 0.001), with a higher mean Society of Thoracic Surgeons (STS) score (7.8% ± 7.1% vs. 7.2 ± 7.5, p < 0.001) and a greater mean aortic gradient (52.4 ± 15.3 vs. 47.3 ± 12.8 mmHg, p < 0.001). Transfemoral TAVR was performed more frequently in women (87.2% vs. 82.1%, p < 0.001), with a higher rate of major vascular complications and life-threatening bleeding (3.9% vs. 2.4%, p = 0.012 and 2.5% vs. 1.4%, p = 0.024). One-year mortality differed between female and male (11.5% vs. 15.0%, p = 0.002), and this difference persisted after adjustment for significant confounding variables (Adj.HR1yr 1.47, 95%IC 1.18–1.82, p < 0.001). Three-year mortality was also significantly lower in women compared with men (19.8% vs. 24.9%, p < 0.001) even after adjustment for age, STS score, eGFR, diabetes and severe COPD (Adj.HR3yr 1.42, 95%IC 1.21–1.68, p < 0.001). These results were confirmed in 689 pairs after propensity score matching. Conclusion: Despite higher rates of peri-procedural complications, women presented better survival than men. This better adaptive response to TAVR may be driven by sex-specific factors.


  • Instantaneous wave-free ratio-guided revascularization of non-culprit lesion in patients with ST-segment elevation myocardial infarction and multivessel coronary disease: design and rationale of the WAVE Registry

    by Carmine Musto, Annunziata Nusca, Giuseppe Biondi-Zoccai, Francesco DE Felice, Massimiliano Scappaticci, Marco S. Nazzaro, Michele M. Viscusi, Andrea Ceccacci, Francesco Versaci

    Article: Instantaneous wave-free ratio-guided revascularization of non-culprit lesion in patients with ST-segment elevation myocardial infarction and multivessel coronary disease: design and rationale of the WAVE Registry - Minerva Cardiology and Angiology 2021 June;69(3):291-8 - Minerva Medica - Journals


  • Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study

    by Carmine Musto, Francesco De Felice, Stefano Rigattieri, Diana Chin, Andrea Marra, Marco Stefano Nazzaro, Alberta Cifarelli, Roberto Violini